Alexandria Real Estate Hits 52-Week Low Amid Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 04 Dec 25
Source: Globenewswire
Alexandria Real Estate Equities Inc's stock fell by 4.28%, hitting a 52-week low following disappointing financial results and legal challenges.
The company reported a significant impairment charge of $323.9 million in Q3 2025, leading to a 19.17% drop in stock price. Additionally, a class action lawsuit has been initiated against the company for misleading statements, raising concerns among investors.
These developments have severely impacted investor confidence, with the stock down 45% year-to-date. The ongoing legal issues and financial struggles may hinder the company's recovery and future growth prospects.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 51.53 USD with a low forecast of 15.84 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
11 Hold
0 Sell
Moderate Buy
Current: 54.610
Low
15.84
Averages
51.53
High
67.00
Current: 54.610
Low
15.84
Averages
51.53
High
67.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
